Number of patients | 73 |
Gender recipient, female | 15 (20.5%) |
Gender donor, female | 36 (49.3%) |
Recipient age, years, (median, range) | 56 (30–69) |
Donor age, years, (median, range) | 67 (21–88) |
Follow-up, months, (median, range) | 48 (2–102) |
Child-Turcotte-Pugh score (A/B/C) at LT, n | 25/16/31 |
Valganciclovir prophylaxis at time of ERC | 34 (47.1%) |
Time of ERC, months since LT, (median, range) | 3.4 (0.3–73) |
Lab/eMELD at LT (mean ± SD) | 27.0 ± 8.7 |
Cold ischemia time, hours (mean ± SD) | 10.0 ± 2,64 |
Indication | |
 Alcoholic cirrhosis | 23 (31.5%) |
 Hepatitis B | 2 (2.7%) |
 Hepatitis C | 11 (15.1%) |
 HCC | 15 (20.5%) |
 PSC | 2 (2.7%) |
 Cryptogenic | 7 (9.6%) |
 Other | 13 (17.8%) |
Death during follow-up | 11 (15.1%) |
Retransplantation | 16 (21.9%) |
Ciclosporin de novo | 51 (69.9%) |
Tacrolimus de novo | 20 (27.4%) |
Mycophenolate mofetil | 61 (83.6%) |
Anastomotic stricture | 34 (46.6%) |
Non-anastomotic stricture | 37 (50.7%) |
Acute rejection | 19 (26.0%) |